Sign in
TerminatedPhase 1

Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia

Key facts

Who runs it
The University of Texas Health Science Center, Houston
Where
Houston, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 1
People taking part
2 people enrolled
Started
16 Jul 2024
Ended
4 Dec 2024
Type of study
Interventional
Treatments tested
  • Naltrexone (Vivitrol)
  • Bupropion
Record updated
16 September 2025
Why it stopped
Unable to recruit eligible participants and expiration of study medication.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • fluent in English
  • Diagnosed with schizophrenia spectrum disorder that is currently stable
  • Report regular cigarette smoking, average cigarette per day ≥ 5 in the past 4 weeks, and present a breath CO≥10 ppm
  • Meet subjective and objective (urinary drug screen) measures of non-opioid use
  • If female, present a negative pregnancy test, not be currently breast feeding, and agree to use acceptable birth control methods and receive periodic pregnancy tests during the course of the study
  • Able to give written informed consent
  • Obtain an Evaluation to Sign Consent (ESC) score above 10

Who cannot take part

  • Previous use of bupropion or naltrexone in the past 30 days
  • Be medically unstable or taking medications that are contraindicated with using naltrexone or bupropion
  • Meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5 )criteria for alcohol and other substance use disorders excluding nicotine and marijuana
  • Report a history of epilepsy, seizure disorder or condition increasing risk of seizure, or head trauma with neurological sequelae
  • Have a current eating disorder
  • Have suicidal or homicidal ideation requiring immediate attention
  • Currently enrolled in treatment for tobacco use

Where in United States

  • The University of Texas Health Science Center at HoustonHouston, United States

About the trial

What the trial wants to find out

The purpose of this study is to assess the feasibility and safety of injectable naltrexone (NTX;380 mg) in conjunction with oral bupropion (BUP; 450 mg daily)NTX-BUP administration among individuals with schizophrenia spectrum disorders that smoke cigarettes and to evaluate change on smoking-related measures and symptoms of schizophrenia.

The group in the trial

  • TreatmentTreatment being tested

    Treatment: Naltrexone (Vivitrol) and Bupropion

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Open-label Pilot Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia
Record updated
16 September 2025